Biotech Stock Performance Review - Vanda Pharma, Verastem, Acceleron Pharma, and Zai Lab

Wednesday, November 15, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, November 15, 2017 /PRNewswire/ --

If you want a Stock Review on VNDA, VSTM, XLRN, or ZLAB then come over

to and sign up for your free customized report. For today, monitors Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), Verastem Inc. (NASDAQ: VSTM), Acceleron Pharma Inc. (NASDAQ: XLRN), and Zai
Lab Ltd (NASDAQ: ZLAB). These companies belong to the Biotechnology space, which is engaged in the research and development of new drugs, medical devices, and procedures. The industry includes the manufacturing and marketing of drugs as a result of direct research and development. These free stocks reports are currently available on Simply sign up for your complimentary member access at:

Vanda Pharmaceuticals 

Washington, the District of Columbia headquartered Vanda Pharmaceuticals Inc.'s stock finished Tuesday's session flat at $12.95 with a total trading volume of 496,938 shares. The stock is trading below their 200-day moving average by 15.50%. Shares of the Company, which focuses on the development and commercialization of products for the treatment of central nervous system disorders, have a Relative Strength Index (RSI) of 28.12.

On November 10th, 2017, Vanda Pharma (VNDA) announced the refusal of the marketing authorization application (MAA) of Fanaptum (oral iloperidone tablets) for the treatment of schizophrenia in adult patients in the European Union. In July 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the Fanaptum MAA. After considering the grounds for VNDA's request for a re-examination of the initial opinion, CHMP re-examined the opinion and confirmed the refusal of the Fanaptum MAA on November 09th, 2017. Your complete research report on VNDA can be retrieved for free at:


Shares in Needham, Massachusetts headquartered Verastem Inc. dropped 3.54%, ending yesterday's session at $3.27 with a total trading volume of 303,227 shares. The stock has gained 0.93% in the previous three months and 191.96% on an YTD basis. The Company's shares are trading 15.84% above their 200-day moving average. Moreover, shares of Verastem, which focuses on discovering and developing drugs for the treatment of cancer, have an RSI of 28.93.  

On November 01st, 2017, Verastem announced that four abstracts have been selected for presentation, including two oral presentations, at the upcoming American Society of Hematology 2017 Annual Meeting to be held from December 09th, 2017, to December 12th, 2017 in Atlanta, GA. Included among the oral presentations are the detailed results from the Phase 3 DUO™ study evaluating the efficacy and safety of duvelisib, a first-in-class oral dual inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma. A free report on VSTM is just a click away at:

Acceleron Pharma 

On Tuesday, Cambridge, Massachusetts headquartered Acceleron Pharma Inc.'s stock saw a drop of 2.57%, to close the day at $34.12. A total volume of 287,426 shares was traded. The Company's shares have advanced 33.70% on an YTD basis. The stock is trading 7.82% above its 200-day moving average. Additionally, shares of Acceleron Pharma, which focuses on the discovery, development, and commercialization of therapeutics for serious and rare diseases, have an RSI of 32.30.  

On November 01st, 2017, Acceleron Pharma announced that two abstracts have been accepted for presentation at the 59th American Society of Hematology Annual Meeting and Exposition to be held from December 09th, 2017, to December 12th, 2017 in Atlanta, Georgia. The oral and poster presentations will include efficacy, duration of response, and long-term safety results from the ongoing Phase-2 studies with luspatercept in myelodysplastic syndromes and sotatercept in myelofibrosis. 

On November 07th, 2017, research firm H.C. Wainwright reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $57 a share to $62 a share. Sign up for your complimentary research report on XLRN at:

Zai Lab 

Shares in Shanghai, China headquartered Zai Lab Ltd, which engages in discovering or licensing, developing, and commercializing proprietary therapeutics for oncology, and autoimmune and infectious disease therapies in China, ended the day 1.97% lower at $26.85. A total volume of 80,650 shares was traded. The stock is trading below its 50-day moving average by 5.37%.

On October 16th, 2017, research firm Leerink Partners initiated an 'Outperform' rating on the Company's stock, with a target price of $42 per share. Register for free on and download the latest research report on ZLAB at:

Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: Phone number:  (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.




Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store